Navigation Links
Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
Date:6/11/2008

ncome of $2.9 million, or $0.11 cents per diluted share for the fourth quarter and a net loss of $10.3 million, or $0.39 cents per share for fiscal 2008. For the comparable periods of fiscal 2007, the amounts were a net loss of $10.8 million, or $0.42 cents per share, and a net loss of $51.2 million, or $2.01 cents per share.

Balance sheet and cash flow

Cash balances have increased by $1.1 million to $91.1 million since the end of the third quarter, and by $6.3 million since the prior fiscal year end of April 27, 2007. The increase in the most recent quarter reflects positive operating cash flow of $7.4 million, offset by the repurchase of 479,000 shares of common stock for $6.2 million.

On April 21, 2008 the company announced the settlement of litigation regarding the $125 million convertible notes. The settlement grants the note holders an option to redeem the notes on December 27, 2011, nine months earlier than the original maturity date. Accordingly, the company has now reclassified this liability to long-term.

Depression update

The company previously announced an effort to identify a financial partner to assist in the execution of the clinical plan developed for the depression indication. This effort remains ongoing, and any progress will be announced at the appropriate time.

Objectives

"During fiscal 2008 the company made significant progress on the objectives outlined by the Board in February 2007," commented Dan Moore, Cyberonics' President and Chief Executive Officer. "In particular, the company has now recorded operating earnings and positive cash flow from operations for the last two quarters of fiscal 2008, and net earnings in the recently completed fourth quarter. Our core U.S. epilepsy business has shown growth for three consecutive quarters, culminating in approximately 20% volume growth in the fourth quarter over the prior year, and our international operations have posted another record year with annu
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
2. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
3. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
4. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
5. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
6. Rosetta Genomics Reports First Quarter 2008 Financial Results
7. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
8. Advance Nanotech Reports First Quarter 2008 Financial Results
9. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
10. Senetek PLC Reports First Quarter 2008 Financial Results
11. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... March 6, 2015 ... 2011 von der Assistance Publique - Hôpitaux ... Sie ist eine französische, gemeinschaftliche, randomisierte Kontrollstudie ... rekrutiert wurden. Verglichen werden Patienten mit fortgeschrittenem ... Harz-Mikrosphären oder Sorafenib behandelt wurden. Die Ergebnisse ...
(Date:3/5/2015)... York (PRWEB) March 05, 2015 LifeCell ... to be able to get an Advanced Semen Analysis ... stress, blaming and guessing are all risk factors for ... the woman is the source of the infertility. Infertility ... LifeCell Dx has the simplest, least complicated and ...
(Date:3/5/2015)... Park, NC (PRWEB) March 05, 2015 ... announced that Pierre Noel, M.D., Professor of Medicine, ... to the Company’s Board of Directors. ... “We are extremely fortunate to have Dr. Noel, ... country’s leading healthcare organization, join Entegrion’s Board. His ...
(Date:3/5/2015)... 5, 2015  In response to the incorrect assertions ... FL on February 12, 2015. Impeto Medical ... financial health and their SUDOSCAN® devices have been proven ... Impeto prefers to have the courts decide this dispute ... than 40 articles written by Key Opinion Leaders, published ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2
... to ZFN Technology To Potentially Improve ... Protein ... SGMO ) today announced that it has entered into a,second Research ... include additional targets for potential improvement,of production cell lines using Sangamo,s ...
... Debiopharm Group,(Debiopharm), a global independent biopharmaceutical development ... oncology, today,announced the establishment of a Debiopharm ... Lausanne (EPFL), focusing on Signal Transduction,in Oncogenesis. ... the objective,of the chair is to leverage ...
... generate antibodies against ... targets provided by Sigma-Aldrich, MUNICH, Germany and ... ) and MorphoSys AG (Frankfurt Stock,Exchange: MOR; Prime ... design, produce and distribute unique,recombinant research antibodies using ...
Cached Biology Technology:Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production 2Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production 3Debiopharm and EPFL Establish an Oncology Chair 2Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies 2Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies 3
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
(Date:1/22/2015)... OXFORD, Conn. , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: ... growing mobile commerce market, reports on the recent success of the Wocket™ ... Wocket smart wallet was named as one of the ... of the "5 Best Products Launched At CES So Far" by Newseveryday.com ...
(Date:1/22/2015)...  Analyst Report Issued by Small Cap IR. In 2011, Nilson ... transactions at merchants on the leading payment cards rose to ... debit, and prepaid cards reached 6.54 billion.  Eight million credit ... usage in 2012, and credit and debit card fraud resulted ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... 2008.- During the 1950s, Austrian and Swiss scientists conducted ... photographs of the glaciers, mountains and valleys. Around the ... months in the region at locations above 5000 metres, ... fifty years later, the black and white photographs taken ...
... to the IOF World Congress on Osteoporosis 2008, at ... 2008. To benefit from lower rates and ... registration fees are available for participants from non-OECD countries ... on-site registration, at higher rates, will be possible. ...
... the European Molecular Biology Laboratory (EMBL) have generated a ... of a vertebrate. With a newly developed microscope scientists ... the first 24 hours in the life of a ... representation of the embryo. The study, published in the ...
Cached Biology News:'Himalaya -- Changing Landscapes' photo exhibition draws attention to the impacts of climate change 2'Himalaya -- Changing Landscapes' photo exhibition draws attention to the impacts of climate change 3Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate 2
CQCS kit for first KR 4i , (first unit)....
... dispenser combining the most versatile features for bulk ... existing Multidrop dispensers. , ,It is designed ... nl up to 2500 l with excellent precision ... for multiple plate formats (96, 384, 1536) including ...
Multidrop Micro high speed 1 l bulk reagent dispenser rapidly, precisely and accurately dispenses microvolumes of 1-50 l into 384- and 96-well microplates....
...
Biology Products: